Claybrook Capital’s Gilead Sciences GILD Stock Holding History

Claybrook Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-512	Closed	-$32K	–	311
2018 Q4	$32K	Buy	+512	New	+$35.8K	0.01%	300

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Claybrook Capital's GILD Position: Q1 2019 in Review

Claybrook Capital sold out of Gilead Sciences (GILD) in Q1 2019, closing a stake of 512 shares — an estimated $32K sold.

Claybrook Capital first reported a position in GILD in Q4 2018 and held it in 1 quarter. The position peaked at $32K in Q4 2018. 1,491 funds tracked by Wall St. Rank hold GILD as of Q1 2019.

Claybrook Capital reported no remaining Gilead Sciences position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 512 Gilead Sciences shares in Q1 2019, an estimated $32K.
Claybrook Capital first reported a position in Gilead Sciences in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Gilead Sciences position peaked at $32K in Q4 2018.
1,491 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.